Clinical Trial Details
| Trial ID: | L3239 |
| Source ID: | NCT00324363 |
| Associated Drug: | Exenatide |
| Title: | Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: exenatide|DRUG: Placebo |
| Outcome Measures: | Primary: To test the hypothesis that exenatide (before morning and evening meals) produces a greater decrease in HbA1c than placebo in patients with type 2 diabetes and inadequate glycemic control taking metformin alone or metformin and sulfonylureas., 16 weeks | Secondary: To compare exenatide and placebo groups with respect to: *safety and tolerability; *proportion of patients achieving HbA1c<=7%; *body weight; *incidence and rate of hypoglycemic events; *glucose measurements, 16 weeks |
| Sponsor/Collaborators: | Sponsor: AstraZeneca | Collaborators: Eli Lilly and Company |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 466 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2006-01 |
| Completion Date: | 2007-04 |
| Results First Posted: | |
| Last Update Posted: | 2015-02-23 |
| Locations: | Research Site, Beijing, China|Research Site, Guangzhou, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Sichuan, China|Research Site, Chennai, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Seoul, Korea, Republic of|Research Site, Sungnam City, Korea, Republic of|Research Site, Chiayi, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan |
| URL: | https://clinicaltrials.gov/show/NCT00324363 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|